Abstract

Aim: The purpose of the study was to describe our surgical technique of salvage robot-assisted radical prostatectomy (sRARP) in patients who underwent primary high-intensity focused ultrasound (HIFU) and to report the perioperative, functional, and oncological outcomes during the first year follow up. The secondary aim of the study was to review the current literature evidence on this topic. Methods: We retrospectively extracted, from our prospective RARP database, all the patients who underwent sRARP for biochemical recurrence after primary HIFU. All the surgical interventions were performed by a single surgeon following our total anatomical reconstruction (TAR) technique. Demographics, perioperative, functional, and oncological results were collected up to one year follow-up. Results: Eleven patients underwent post-HIFU sRARP with TAR technique at our institution. All the surgical procedures were uneventful. All the complication recorded were classified as Clavien-Dindo Grade I. Continence rate at 1-, 3-, 6-, and 12-month post intervention was 36.3%, 45.5%, 63.6 %, and 81.1%, respectively. Medium PSA at 12 months follow-up was 0.2 ng/mL (SD 0.01), with no Biochemical Failure (BCF) recorded. Conclusion: sRARP with TAR technique is a safe and feasible procedure in patients with BCF after primary HIFU. No major complications were recorded, with good oncological and functional results after one year follow up.

Highlights

  • The prostate cancer (PCa) screening strategies, mainly based on serum prostate-specific antigen (PSA) levels evaluation, currently result in an overdiagnosis of low-/intermediate-grade organ-confined neoplasms[1,2]

  • A number of patients with intermediate risk PCa are eligible for active radical treatment [i.e., radical prostatectomy (RP) or radiotherapy] which may be classified as “overtreatment”, considering the potential side effects[4,5,6]

  • We retrospectively evaluated our prospectively maintained RARP database and extracted patients who underwent salvage robot-assisted radical prostatectomy (sRARP) with total anatomical reconstruction (TAR) technique for biochemical recurrence after primary high-intensity focused ultrasound (HIFU) from January 2015 to June 2020

Read more

Summary

Introduction

The prostate cancer (PCa) screening strategies, mainly based on serum prostate-specific antigen (PSA) levels evaluation, currently result in an overdiagnosis of low-/intermediate-grade organ-confined neoplasms[1,2]. Some of these patients (i.e., low risk PCa with life expectancy > 10 years) can be safely treated with active surveillance[3]. On the other hand, considering that PCa is often multi-focal, a proportion of patients will develop local recurrent disease

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call